Expression of CYP2W1 in colon tumors: Regulation by gene methylation

Pharmacogenomics

Volumn 8, Issue 10, 2007, Pages 1315-1325

  Gomez, Alvin ^a   Karlgren, Maria ^a   Edler, David ^b   Bernal, Maria Luisa ^c   Mkrtchian, Souren ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Colon cancer; DNA methylation; Pharmacoepigenetics

Indexed keywords

BISULFITE; CYTOCHROME P450 2W1; MESSENGER RNA; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; COLON CARCINOMA; COLON TUMOR; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DRUG TARGETING; EXON; FETUS; GENE EXPRESSION; GENE INDUCTION; GENETIC LINKAGE; GENETIC REGULATION; HUMAN; HUMAN CELL; INTRON; NONHUMAN; PHENOTYPE; PROTEIN METHYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SEQUENCE ANALYSIS; TISSUE SPECIFICITY; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COLON; COLONIC NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION; REFERENCE VALUES; RNA, MESSENGER;

RATTUS;

EID: 36148931473     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.10.1315     Document Type: Article

References (43)

1. Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes. J. Mol. Biol. 196(2), 261-282 (1987).
2. Robertson KD, Wolffe AP: DNA methylation in health and disease. Nat. Rev. Genet. 1(1), 11-19 (2000).
3. Tokizane T, Shlina H, Igawa M et al.: Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin. Cancer Res. 11(16), 5793-5801 (2005).
4. Iguchi-Ariga SM, Schaffner W: CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev. 3(5), 612-619 (1989).
5. Tate PH, Bird AP: Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 3(2), 226-231 (1993).
6. Kass SU, Landsberger N, Wolffe AP: DNA methylation directs a time-dependent repression of transcription initiation. Curr. Biol. 7(3), 157-165 (1997).
7. Martinowich K, Hattori D, Wu H et al.: DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302(5646), 890-893 (2003).
8. Hashimshony T, Zhang J, Keshet I, Bustin M, Cedar H: The role of DNA methylation in setting up chromatin structure during development. Nat. Genet. 34(2), 187-192 (2003).
9. Jones PA, Takai D: The role of DNA methylation in mammalian epigenetics. Science 293(5532), 1068-1070 (2001).
10. Ballestar E, Esteller M: Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem. Cell Biol. 83(3), 374-384 (2005).
11. Nan X, Ng HH, Johnson CA et al.: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683), 386-389 (1998).
12. Frigola J, Sole X, Paz MF et al.: Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum. Mol. Genet. 14(2), 319-326 (2005).
13. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 21(35), 5400-5413 (2002).
14. Rodriguez J, Frigola J, Vendrell E et al.: chromosomal instability correlates with genome-wide dna demethylation in human primary colorectal cancers. Cancer Res. 66(17), 8462-9468 (2006).
15. Bariol C, Suter C, Cheong K et al.: The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am. J. Pathol. 162(4), 1361-1371 (2003).
16. Benbrahim-Tallaa L, Waterland RA, Styblo M, Achanzar WE, Webber MM, Waalkes MP: Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol. Appl. Pharmacol. 206(3), 288-298 (2005).
17. Nishigaki M, Aoyagi K, Danjoh I et al.: Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res. 65(6), 2115-2124 (2005).
18. Tanaka H, Deng G, Matsuzaki K et al.: BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int. J. Cancer. 118(11), 2765-2771 (2006).
19. Rhee I, Bachman KE, Park BH et al.: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416(6880), 552-556 (2002).
20. McKie AB, Douglas DA, Olijslagers, S et al.: Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 24(13), 2166-2174 (2005).
21. Yamada D, Kikuchi S, Williams YN et al.: Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int. J. Cancer. 118(4), 916-923 (2006).
22. Merlo A, Herman JG, Mao L et al.: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1(7), 686-692 (1995).
23. Robertson KD, Jones PA: The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell Biol. 18(11), 6457-6473 (1998).
24. Paz MF, Wei S, Cigudosa JC et al.: Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficienf in DNA methyltransferases. Hum. Mol. Genet 12(17), 2209-2219 (2003).
25. Toyooka KO, Toyooka S, Virmani AK et al.: Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 61(11), 4556-4560 (2001).
26. Esteller M: Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 45 629-656 (2005).
27. Jin B, Park DW, Nam KW, Oh GT, Lee YS, Ryu DY: CpG methylation of the mouse CYP1A2 promoter. Toxicol. Lett. 152(1), 11-18 (2004).
28. Vieira I, Sonnier M, Cresteil T: Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur. J. Biochem. 238(2), 476-483 (1996).
29. Hammons GJ, Yan-Sanders Y, Jin B, Blann E, Kadlubar FF, Lyn-Cook BD: Specific site methylation in the 5′-flanking region of CYP1A2 interindividual differences in human livers. Life Sci. 69(7), 839-845 (2001).
30. Oyama T, Kagawa N, Kunugita N et al.: Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front. Biosci. 9 1967-1976 (2004).
31. Murray GI, Taylor MC, McFadyen MC et al.: Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57(14), 3026-3031 (1997).
32. Rieger MA, Ebner R, Bell DR et al.: Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res. 64(7), 2357-2364 (2004).
33. Jiang JG, Chen CL, Card JW et al.: Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 65(11), 4707-4715 (2005).
34. Karlgren M, Gomez A, Stark K et al.: Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem. Biophys. Res. Commun. 341(2), 451-458 (2006).
35. Backlund M, Ingelman-Sundberg M: Different structural requirements of the ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation. Mol. Pharmacol. 65(2), 416-425 (2004).
36. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M: Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun. 284(2), 455-460 (2001).
37. Karlgren M, Backlund M, Johansson I, Oscarson M, Ingelman-Sundberg M: Characterization and time distribution of a novel human cytochrome P450-CYP2U1. Biochem. Biophys. Res. Commun. 315(3), 679-685 (2004).
38. Carriere V, Chambaz J, Rousset M: Intestinal responses to xenobiotics. Toxicol. In Vitro. 15(4-5), 373-378 (2001).
39. Wu Z, Sohl C, Shimada T, Guengerich F: Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol. Pharmacol. 69(6), 2007-2014 (2006).
40. Rodriguez-Antona C, Ingelman-Sundberg M: Cytochrome P450 pharmacogenetics and cancel. Oncogene 25(11), 1679-1691 (2006).
41. Gold P, Freedman SO: Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 122(3), 467-481 (1965).
42. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
43. Kumarakulasingham M, Rooney PH, Dundas SR et al.: Cytochrome P450 profile of colorectal cancer: identification of markers of prognosis. Clin. Cancer Res. 11(10), 3758-3765.